In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pharmacia & Upjohn acquires Sugen for $728mm

Executive Summary

In a stock-for-stock merger valued at about $728mm, Pharmacia & Upjohn Inc. will acquire Sugen Inc. (development-stage cancer therapies). Each share of Sugen will be exchanged for about $31 worth of Sugen's stock, a (pr)47% premium to P&U's 10-day trailing average price of $21.08.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies